Friday, November 30, 2018
Axonics Modulation Technologies, Inc., a medical device company focused on the design, development and commercialization of innovative and minimally invasive solutions for sacral neuromodulation ("SNM") treatment of bladder and bowel dysfunction , today announced that the AXONICS r-SNM ™ system in the online catalog of the supply chain of the national Health service (NHS Supply Chain, "NHS SC") is listed in the UK, which is a broad commercial distribution of NHS clinics in England.
Inclusion in the NHS SC online catalog is an important step towards a wider availability of new medical technologies and orders for the company's product are already being received and shipped. The Axonics r-SNM System is the first SNM rechargeable system approved in the UK for overactive bladder, faecal incontinence and urinary retention patients.
Raymond W. Cohen, CEO of Axonics, commented, "Following the NHS efforts to centralize the purchase of medical devices for its hospitals, inclusion in the NHS SC online catalog is critical to operating in the UK. We are now well positioned to help physicians select and implant the Axonics solution for the benefit of a broader patient population. These early orders are important as we establish our brand and set up referral sites in England. With the cost savings of our long-lasting r-SNM implant and innovative product features, we are optimistic that we will continue to penetrate the market in the UK in 2019. "
About the British National Health Service (NHS) Supply Chain
NHS Supply Chain ("NHS SC") provides patient-centered healthcare products and supply chain services to the UK NHS. NHS SC's end-to-end supply chain services include procurement, logistics, e-commerce, and customer and supplier support. The ecommerce website spans 315,000 product lines, from associations to MRI scanners, and is poised to achieve £ 300 million in procurement efficiencies. NHS SC works with suppliers to deliver high-quality, cost-effective products to more than 1,000 NHS hospital and healthcare organizations.
About bladder hyperactivity and sacral neuromodulation
In the US and Europe, an estimated 85 million adults are affected by bladder hyperactivity. Another 40 million adults are reported to suffer from fecal incontinence. SNM therapy is an effective and long-lasting treatment that has been widely used in Europe and the US over the last two decades and has been adopted by health insurers. SNM is the only treatment for bladder hyperactivity with proven clinical superiority over standard medical therapy and patients with bladder hyperactivity who receive SNM report significantly higher quality of life than patients undergoing drug treatment.
About Axonics Modulation Technologies, Inc.
Headquartered in Irvine, California, Axonics focuses on the development and commercialization of a novel, implantable SNM system for patients with urinary and bowel disorders and on revolutionizing the SNM market, which is currently dominated by a single major player. The Axonics r-SNM system is the first rechargeable sacral neuromodulation system approved for sale in Europe, Canada and Australia. The r-SNM system consists of a temporary external one-way trial system, a miniaturized, rechargeable, long-lasting stimulator that will operate for at least 15 years, an armature electrode, as well as patient-friendly accessories such as a charging system optimized for minimal charging time and without heating, a small, user-friendly patient remote control and an intuitive programmer for clinicians that facilitates electrode placement and programming. For more information, visit the company website atwww.axonicsmodulation.com .
Forward-looking statements
Statements in this press release that relate to future plans, events, projections or results are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "planned," "expects," "believes," "assumes "," Designed "and similar expressions are intended to identify such forward-looking statements. While these forward-looking statements are based on management's current expectations and beliefs, they are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those expressed in this news release, including risks and rewards uncertaintieswww.sec.gov are available. Readers are cautioned not to place undue reliance on these forward-looking statements, as they are only valid at this time. Unless required by law, Axonics assumes no obligation to update or revise any forward-looking statements as a result of new information, changed circumstances or unforeseen events.
The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version published in the original is legal. Compare translations with the original language version of the publication.
Contacts
Contact Axonics
Axonics Modulation Technologies, Inc.
Dan Dearen, 1-949-396-6320
President & Chief Financial Officer
ir@axonics.com
Contact Investor and Media
W2Opure
Matt Clawson, 1-949-370-8500
mclawson@w2ogroup.com
